Finerenone in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• The FIDELITY post hoc analysis explored outcomes in a larger chronic kidney disease (CKD) population from the FIDELIO-DKD and FIGARO-DKD trials.
• Patients with Type 2 diabetes (T2D) and CKD treated with optimised renin-angiotensin system blockage were randomised to finerenone or placebo.
• The cardiorenal benefits of finerenone were consistent irrespective of baseline glucagon-like peptide-1 receptor agonist (GLP-1RA) usage on cardiovascular (CV) composite outcomes in patients with T2D and CKD.
• The reduction in urine albumin-to-creatinine ratio (UACR) with finerenone was greater among patients with baseline GLP-1RA use.
• Finerenone increased the incidence of hyperkalaemia irrespective of baseline GLP-1RA use.